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Abstract. Alzheimer’s disease (AD) is characterized by plaques of amyloid-β (Aβ) peptide, cleaved from amyloid-β protein
precursor (AβPP). Our hypothesis is that lifespan profiles of AD-associated mRNA and protein levels in monkeys would differ
from mice and that differential lifespan expression profiles would be useful to understand human AD pathogenesis. We compared
profiles of AβPP mRNA, AβPP protein, and Aβ levels in rodents and primates. We also tracked a transcriptional regulator of the
AβPP gene, specificity protein 1 (SP1), and the β amyloid precursor cleaving enzyme (BACE1). In mice, AβPP and SP1 mRNA
and their protein products were elevated late in life; Aβ levels declined in old age. In monkeys, SP1, AβPP, and BACE1 mRNA
declined in old age, while protein products and Aβ levels rose. Proteolytic processing in both species did not match production of
Aβ. In primates, AβPP and SP1 mRNA levels coordinate, but an inverse relationship exists with corresponding protein products
as well as Aβ levels. Comparison of human DNA and mRNA sequences to monkey and mouse counterparts revealed structural
features that may explain differences in transcriptional and translational processing. These findings are important for selecting
appropriate models for AD and other age-related diseases.
Keywords: Amyloid-β protein precursor (AβPP), amyloidogenesis, BACE1, development, primates, rodents, specificity protein
1 (SP1), transcription
INTRODUCTION
Alzheimer’s disease (AD) is a progressive, irre-
versible neurodegenerative disorder resulting in mem-
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ory loss, dementia, and death. It is characterized
by senile plaques composed of aggregated amyloid-
β (Aβ), neurofibrillary tangles, and synaptic loss in
the brain [1–6]. Autosomally inherited AD can be
caused by mutations in the amyloid-β protein precur-
sor (AβPP) and presenilin 1 (PSEN1) genes. However,
this accounts for no more than 10% of cases [6]. In
over 90% of cases, patients have “sporadic” AD not
characterized by autosomal inheritance. The APOE
ε4 allele [7,8], the only confirmed genetic risk factor
for sporadic AD, accounts for a minority of the disor-
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der [9], and the etiology of most sporadic AD cases
remains unknown.
The accumulation of amyloidogenic Aβ peptides
from cleavage of AβPP has been studied extensive-
ly. Human AβPP and/or PS-1 transgenic rodent ani-
mal models [10–14] are widely used to study molec-
ular and biological processes underlying AD patho-
genesis. While these animal models demonstrate AD-
like pathologies and behavioral changes compared to
wild-type animals, they carry mutant forms of AD-
related genes, driven by promoters other than those of
the respective genes. Thus, AβPP is overexpressed
and processed to speed up AD pathogenesis in a man-
ner that may not be clinically relevant. Transgenic
human AβPP in these rodents is cleaved by intrinsic
β-secretase (BACE1) to produce Aβ. The preferred
cleavage site by rodent BACE1 in human AβPP is
different from that by which human BACE1 cleaves
AβPP [15].
Although rodents and primates share more than
95% amino acid sequence homology in their respec-
tive AβPP proteins [1], the amyloid products from the
two differ. Murid rodents do not aggregate Aβ pep-
tides and, therefore, are non plaque-forming, but pri-
mates are human-like in their ability for Aβ aggrega-
tion to form senile plaques. The Aβ peptide sequence
from primates and murid rodents differ in three amino
acids at residues 5 (R→G), 10 (Y→F), and 13 (H→R).
However, the primary sequence difference may not ex-
plain plaque-forming or non-plaque-forming nature of
the peptides, since in vitro experiments [15,17] indi-
cate that either peptide could aggregate. A difference
has been noted in the 5’-untranslated region of the
mRNA of non-plaque-forming versus plaque-forming
mammalian species, specifically, the absence of a “CA-
GA” box in non-plaque-forming species mRNA [18].
However, differences in processing of AβPP or Aβ
metabolism in vivomay, likewise, determine amyloido-
genesis. This is especially true if physiologic manifes-
tations of aging are considered, and this paper seeks to
address this issue.
The 5’-flanking regulatory region of the AβPP gene
is rich in GC box elements and contains consensus
sites that are recognized by several transcription fac-
tors, including specificity protein 1 (SP1) [19,20]. SP1
binds to both the human and rat AβPP promoters and
accelerates the production of AβPP mRNA [21–23],
which can be further spliced to generate several cell-
specific species. SP1 belongs to a family of zinc finger
protein (ZFP) transcription factors that includes oth-
er members such as SP2, SP3, and SP4 [24,25]. SP1
is a transcription factor involved in the pathology of
AD [26,27]. Furthermore, SP1 regulates the expres-
sion of BACE1 [28], the main form of β-secretase that
cleaves AβPP to generate Aβ [29]. Likewise, silencing
SP1 gene dramatically reduces AβPP promoter activi-
ty [26]. In addition, SP1 regulates the expression of the
microtubule associated protein tau (MAPT) gene [30].
The buildup of hyperphosphorylated tau protein results
in the formation of the pathogenic tangles found in AD
and some other neurodegenerative disorders like Pick’s
disease [27].
AD incidence increases exponentially after 65 years
of age, making age the greatest risk factor for AD [31].
It is well known that the most common animal model
species for AD (mouse) does not develop any similar
conditions, requiring the use of transgenics or drug-
induced defects. Monkeys, on the other hand, have
shown the spontaneous presence of Aβ plaques [32]
and many genes known to be involved in human neu-
rological disorders have been shown to be present and
regulated in cynomolgus monkeys [33]. Likewise, ad-
ministration of a modified version of the Cambridge
Automated Neuropsychological Test Battery has deter-
mined that aged monkeys reveal patterns of age-related
cognitive impairment that mirror in quality and severity
those of aged humans [34].
We hypothesize that profiles of gene expression
and protein levels of the AD-critical SP1, AβPP, and
BACE1 genes in mice would differ over the lifespan in
a non-trivial fashion from those of a species closer to
human, specifically cynomolgus monkey. These dif-
ferences would be qualitative and appear at transcrip-
tional, translational, and protein processing levels of
gene expression. Therefore, we examined the path-
ways of AβPP production, processing, and accumula-
tion of its Aβ cleavage product as a function of age.
We compared differences in AD-related gene expres-
sion between rodents and primates. Our results sug-
gest fundamental differences between rodents and pri-
mates in expression and processing of important AD-
related genes and proteins. These differences occur at
transcriptional, translational, and post-translation lev-
els, potentially affecting applicability of animal model
studies at several stages of understanding AD.
MATERIALS AND METHODS
Animals and tissues
The C57Bl/6 mice were bred in house at Universi-
ty of Rhode Island. Male pups from different dams
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were pulled and selected randomly at the time of sac-
rifice. Brains were dissected at different ages, specif-
ically three mice at each postnatal day (PND) 5, 20,
180, 365, and 630, and brain frontal cortex tissues were
stored at −80◦C until use. The cynomolgus monkey
brain cortex tissues were obtained from National Insti-
tutes of Health (NIH) and were control monkeys from
two separate studies [35]. They were kept at the NIH
facility until termination at 3–6, 12, and 23 years of age,
three animals at each of three timepoints. All animal
procedures were conducted under the supervision of a
licensed veterinarian according to a National Institute
on Environmental Health Sciences–NIH-approved an-
imal protocol. The tissues were kept frozen until use
in our study.
Total RNA isolation, synthesis of cDNA, and Real
Time PCR
RNA from brain tissue was isolated according to the
TRIzol method (Invitrogen, Carlsbad, CA). The RNA
was reverse transcribed to obtain cDNAs, catalyzed by
SuperScript III (Invitrogen) reverse transcriptase (RT).
The RNA/primer mixture containing 500 ng of total
RNA, 1µl of 10mMdNTPmixture, and 1µl Oligo(dT)
were incubated at 65◦C for 5 min. A reaction mixture
containing 2 µl of 10x RT buffer [200 mM Tris–HCl
(pH 8.4), 500 mM KCl], 4 µl of 25 mM MgCl2, 2 µl
of 0.1 M DTT and 1 µl of RNaseOUT (Invitrogen) re-
combinant RNase inhibitor (40 U/µl) was added. One
microliter of SuperScript III RT (200 U/µl) was then
added and incubated at 50◦C for 50 min. The reaction
was terminated at 85◦C for 5 min. One microliter of
RNase H was added and the reaction was incubated
for 20 min at 37◦C. The resulting cDNA was stored
at −20◦C and used in the real time PCR step. The
primer pairs used for mouse AβPP, SP1, and β-actin
are described in Table 1. Each real time PCR reac-
tion mix contained 1 µl of cDNA, 1 µl of primer mix
(final concentration 200 nM), 10.5 µl of nuclease free
water and 12.5 µl SYBR GREEN PCR Master Mix
(Applied Biosystems, CA). Each sample was done in
triplicate. Real Time PCR was conducted for all above
genes with respective primer pairs in a 7500 Real-Time
PCR System following standard protocol. The initial
step was 50◦C for 2 min followed by 95◦C for 10 min,
then 40 cycles of 95◦C for 15 sec and 60◦C for 1 min.
Real time PCR products were checkedwith agarose gel
to confirm no non-specific products formed. Results
were analyzed with 7500 system software with rela-
tive quantification method using β-actin or GAPDH as
endogenous controls.
Western blot
Brain tissues were homogenized in RIPA buffer con-
taining protease inhibitor cocktail (Promega), incubat-
ed on ice for one hour then centrifuged at 3500 x g for
20 min [26]. The supernatant was collected and used
for western blot. Protein concentrationwas determined
by BCA kit (Pierce Biotechnology, Inc. Rockford, IL).
A 10 µg aliquot of total protein from each sample was
applied for western blot. Protein samples were dena-
tured and resolved in 8% SDS-PAGE then transferred
to PVDF membrane. The membrane was blocked with
5% non-fat milk in Tris buffered saline (TBS, pH 7.4)
for one hour, then 22C11 AβPP N-terminal specific
antibody (1:1000) was incubated with 5% milk in TBS
overnight at 4◦C. For SP1, the membrane was incu-
bated with SP1 (H-225) polyclonal antibody (1:200).
The membrane was washed with TBST (TBS + 0.5%
Tween-20) 4 times before adding horseradish peroxi-
dase conjugated goat anti-rabbit IgG (1:1000, Pierce).
Eachmembranewas incubated at room temperature for
60min followed by sequential wash with TBST 4 times
and TBS 4 times then developed by Amersham ECL
PlusWestern Blotting Detection System and visualized
with Typhoon 9410 MultiMode Scanner. Signals were
normalized to GAPDH or Actin signal of same lanes.
Amyloid-β1−40 assay
The levels of Aβweremeasuredwith humanAβ1−40
assay kits (Immuno-Biological Laboratories, Gunma
Japan). These kits were designed as solid phase sand-
wich ELISA with highly specific antibody. The assay
conditions were followed according to the method de-
scribed previously [36]with slightmodifications. Brain
tissue was homogenized in Tris-Saline (TS) [50 mM
Tris-HCl buffer, pH 7.4; 150 mM NaCl; 1 µg/mL
TLCK (N–Alpha–p–tosyl–L–Lysine chloromethyl ke-
tone); 1 µg/mL antipain; 0.5 mM DIFP (Diisopropyl
fluorophosphates); 1 mM PMSF; 1 mM NaF; 0.25%
sodium deoxycholate; 0.5% SDS; 0.1% Protease In-
hibitor cocktail], incubated on ice for one hour, then
centrifuged at 3500 g for 20 min at 4◦C. The resultant
supernatant was collected and diluted by EIA buffer
(supplied with the kit) to 1 µg/ µl (100 µg of protein in
100 µl EIA buffer) and assay standards were added to
a 96 well plate (pre-coated with anti-human Aβ35−40
(1A10)Mouse IgG monoclonal antibody) and incubat-
ed overnight at 4◦C. The wells were washed 7 times
with EIA buffer. Then 100 µl of labeled antibody was
added to each well containing sample or standard and
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Table 1
Oligomers for real-time PCR of mouse and monkey mRNA
Gene Organism Orientation Sequence Reference Location
AβPP mouse Sense 5’–TGC AGC AGA ACG GAT ATG AG–3’ NM 007471.2 2175–2194
AβPP mouse antisense 5’–ACA CCG ATG GGT AGT GAA GC–3’ NM 007471.2 2285–2304
SP1 mouse Sense 5’–CCT GAA TGG GAA CAT CAC CT–3’ NM 013672.2 874–893
SP1 mouse antisense 5’–ACC AAG CTG GCA GAA CTG AT–3’ NM 013672.2 1010–1029
β-actin mouse Sense 5’–TGT TAC CAA CTG GGA CGA CA–3’ NM 007393.3 304–323
β-actin mouse antisense 5’–TCT CAG CTG TGG TGG TGA AG–3’ NM 007393.3 676–695
AβPP monkey Sense 5’–GCT GGC TGA ACC CCA GAT–3’ M58727.1 227–244
AβPP monkey antisense 5’–CCC ACT TCC CAT TCT GGA CAT–3’ M58727.1 280–300
BACE1 monkey Sense 5’–TTT GTG GAG ATG GTG GAC AA–3’ XM 001093566.1a 624–643
BACE1 monkey antisense 5’–CAG CAC CCA CTG CAA AGT TA–3’ XM 001093566.1a 737–756
SP1 monkey Sense 5’–CAA GCC CAA ACA ATC ACC TT–3’ XM 001104877.1a 1575–1594b
SP1 monkey antisense 5’–CAA TGG GTG TGA GAG TGG TG–3’ XM 001104877.1a 1640–1659b
GAPDH monkey Sense 5’–TGA AGC AGG CGT CGG AGG G–3’ DQ464111.1 115–133
GAPDH monkey antisense 5’–CGA AGG TGG AAG AGT GGG TG–3’ DQ464111.1 197–216
aSequence from rhesus monkey.
bA single–base mismatch exists (underlined) between rhesus sequence and oligomer.
incubated at 4◦C for 1 hour. The wells were washed
9 times with EIA buffer followed by the addition of
100 µl of TMB buffer and incubated in the dark for
30 min at room temperature. The reaction was stopped
by adding 100 µl of 1N H2SO4 and colorimetric ab-
sorption was taken at 450 nm. The levels of Aβ in
the test samples were calculated relative to the standard
curve generated on each plate.
BACE1 activity assay
β-secretase activity was conducted with BACE1 ac-
tivity kit (R&D Systems, Inc. Minneapolis, MN) fol-
lowing manufacturer’s protocol with small modifica-
tions. The enzymatic reaction for secretase activitywas
carried out in the black uncoated microplate provided,
with controls provided in the kit. Total protein from
brain tissue homogenatewas diluted to 1µg/µl with 1X
Cell Extraction Buffer. Then 50 µl of protein sample
was added to each well. Each sample was run in dupli-
cates for greater accuracy. Next, to each well, 50 µl of
2X Reaction Buffer was added to each well plus 5 µl of
substrate at room temperature to each well. Negative
controls run were a) no protein sample and b) no sub-
strate. The plate was covered by provided film, tapped
gently to mix, and incubated at 37◦C for 2 hours in the
dark. The plate was read on a fluorescent microplate
reader using light filters that allow for wavelength exci-
tation between 335–355 nm and emitted light between
495–510 nm was recorded.
Statistical analysis
Results from mRNA expression, protein, or peptide
level, and enzymatic activity assays were subject to t-
test against “adult” data points, “adult” defined as PND
365 for mice and 12 years age for monkeys. Average
values with p < 0.05 vs. their respective “adult” data
points were deemed significant.
DNA sequence homology analysis of mouse and
monkey SP1 and AβPP genes versus human SP1 and
AβPP genes
The NCBI human genome database (build 36.2) was
consulted for the reference sequences of the humanSP1
and AβPP genomic sequences. A portion of reference
sequenceNC 000012 from 52056246 to 52096497was
selected for SP1 BLAST, and the AβPP reference se-
quence NG 007376.1 was used for BLAST. Cynomol-
gus monkey (Macaca fascicularis) genomic sequences
were not available; therefore, rhesus monkey (Macaca
mulatta) sequences were used. BLAST comparison of
the available cynomolgus sequence versus rhesus se-
quences showed 99% or greater homology (data not
shown) between the two. Each sequence was used to
probe the rhesus monkey (build 1.1) and mouse (build
37.1) NCBI reference genome databases. In addition,
sequences of 4 kb upstreamof the+1 transcription start
site (TSS) of the SP1 genes of mouse, rhesus monkey,
and human were extracted from their respective NCBI
genomic databases, and the monkey and mouse SP1
sequences were each compared with the human SP1
sequence via ClustalX [37].
Transcription factor binding site analysis of
promoters of SP1 for human, mouse, and monkey
Sequences 4 kb upstream of the +1 TSS of the SP1
genes of mouse, rhesus monkey, and human were used
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to search for putative transcription factor binding sites
via the MatInspector utility of the Genomatix analysis
package [38]. Results for each species were compared,
and predicted factor binding sites unique to mouse or
shared bymonkey and human but absent in mousewere
recorded.
Motif analysis of 5’- and 3’-untranslated regions
(UTRs) of AβPP for human, mouse, and monkey
The RegRNA database/analysis utility [39] was em-
ployed to search the sequences of the human (Gen-
Bank Accession #NM 000484), cynomolgus monkey
(M58727), and mouse (NM 007471) AβPP mRNA 5’-
and 3’-UTRs. For consistency with our previous publi-
cations, the+1 transcription start site (TSS) producing
a 147bp 5’-UTR [19]was selected for the humanAβPP
sequence rather than a further-upstream TSS that pro-
duces a 194bp 5’-UTR. UTR sequences were searched
for conventional regulatory motifs and miRNA homol-
ogy sites.
RESULTS
Our purpose in comparing AD-associated gene ex-
pression between monkeys and mice is to establish
comparative non-pathological “baselines” for disease-
critical genes and their protein products. We hy-
pothesized that non-trivial, qualitative differences ex-
ist between primate and rodent expression in funda-
mental AD-associated genes at transcriptional, post-
transcriptional, and protein processing levels. Profil-
ing of AD-associated gene expression and protein lev-
els in the lifespan of monkeys and mice produces con-
trol profiles of animal models, which develop an un-
derstanding of “baseline” normal aging effects on tran-
scriptional, translational, and post-translational mech-
anisms. These baselines then form a basis for evalu-
ating overall model performance in comparison to hu-
man aging and pathological processes. The data report-
ed below are the results of measuring AβPP, BACE1,
and SP1 gene expression as well as their protein lev-
els in the brain frontal cortices of wild-type mice and
primates. In addition, comparative results of pertinent
DNA and mRNA sequences and sub-sequences of the
AβPP, BACE1, and SP1 genes are presented.
AβPP, BACE1, and SP1 mRNA expression in mice at
different ages
The mRNA expression of AβPP and SP1 was exam-
ined by real time PCR at six different times within the
mouse life span and normalized to β-actin PCR signal,
PND5 through630. Inmice, normalizedAβPPmRNA
signal increased dramatically from PND 5 to PND 20,
remained steady throughout adulthood, and increased
again upon aging. Normalized SP1 mRNA expression
showed (Fig. 1A) the same trend as that of the AβPP
mRNA (Fig. 1B); however, normalizedBACE1mRNA
did not show any trend with aging (data not shown).
AβPP, SP1, and Aβ1−40 levels in mice at different ages
AβPP and SP1 protein levels were determined by
Western blot analysis and normalized to β-actin, and
Aβ levels were measured using an ELISA assay
(Fig. 2A, 2B, and 2C). Normalized AβPP levels slight-
ly increased during development, remained steady dur-
ing adulthood, and sharply rose in old age (Fig. 2A).
Normalized SP1 levels did not change on PND 20 but
showed a similar increase in old age (Fig. 2B). Aβ lev-
els on the other hand dropped on PND 20, rose to adult
levels by PND 365, but exhibited a sharp decline in old
age at PND 630 (Fig. 2C). The profile of the SP1 and
AβPP proteins was similar to the pattern of AβPP and
SP1 mRNA expression in old age (Fig. 1 versus 2).
AβPP, BACE1, and SP1 mRNA expression in monkeys
at different ages
In the three monkey age groups, both GAPDH-
normalizedAβPP and normalizedBACE1mRNAwere
independently elevated in the adult group (12-year old),
but decreased in the aged 23-year old group (Fig. 3A
and 3B). As was the case in mice, normalized SP1 mR-
NA expression showed the same trend as normalized
mRNA of AβPP (Fig. 1 versus 2). Unlike in mice,
BACE1 mRNA decreased in monkey.
AβPP, SP1 protein expression, and Aβ1−40 levels in
monkeys at different ages
The total β-actin-normalized AβPP protein level in
monkeys increased linearly as they aged (Fig. 4A). The
plaque-formingprimates accumulatedAβPP protein in
their brain as they aged despite their inverse relation-
ship to the AβPP mRNA (Fig. 3 vs. 4). Normalized
SP1 levels, on the other hand, remained steady during
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Fig. 1. Lifetime mRNA expression changes in AD related genes (SP1, AβPP) in the mouse brain cortex. Relative quantification was measured by
using 7500 Real-Time PCR System (Applied Biosystems, CA) with β-actin serving as the endogenous control. A) Relative SP1 mRNA signal.
B) Relative AβPP mRNA signal. Each data point in the curve is the mean + SEM (n = 3–4 animals). “∗” denotes significant difference for SP1
or AβPP mRNA time point when compared to that of PND 365.
adulthoodbut sharply rose in old age (Fig. 4B). In mon-
keys, there was an age-dependent increase in Aβ1−40
levels (Fig. 4C), which was consistent with normalized
AβPP protein levels.
BACE1 activity in mice and monkeys at different ages
BACE1 is the proteolytic enzyme that generates the
N-terminus of Aβ peptide. Our study showed that
BACE1 activity remained relatively steady in young
and aging mice (Fig. 5A). In monkeys, BACE1 activity
appears to decrease in old age (Fig. 5B), although this
decrease is not significant at p < 0.05. In bothmice and
monkeys, BACE1 activity does not appear to follow the
same pattern as AβPP or Aβ levels.
Genomic sequence homologies of monkey and mouse
SP1 and AβPP sequences with human sequence
Structural similarities and differences in genomic
sequences are often reflected in differences in tran-
scription and hnRNA processing. We examined the
respective SP1 genes of monkey (40 kb) and mouse
(39 kb) vs. human (40 kb) genomic sequences via
BLAST. When the mouse genomic sequence database
was BLAST probed with the human genomic sequence
for SP1 (Fig. 6A), coverage of homologous regions
attained 19% of total human genomic sequence with
an identity of 91% over the longest homologous sub-
sequence. Coverage of homologous regions between
human (300 kb) AβPP and mouse (290 kb) AβPP se-
quences (Fig. 6B) was 3%, with an identity of 85%
over the longest homologous sub-sequence. Compar-
ison of monkey and human SP1 genomic sequences
(Fig. 6C) revealed 63% coveragewith a 95% homology
for the longest homologous sub-sequence. Coverage
of homologous regions between human and monkey
(300 kb) AβPP sequences (Fig. 6D) was 91% with an
identity of 91% over the longest homologous sequence.
These differences betweenmouse andmonkey in struc-
tural homology to the humanAD-related genes SP1 and
AβPP are not unexpectedand indicate that fundamental
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Fig. 2. Lifetime profile of AD related proteins (AβPP, SP1 Aβ) in the mouse brain. Protein from cortical tissue of wild-type mice was isolated,
equal protein amounts were loaded and probed with 22C11 AβPP N-terminus antibody with SDS–PAGE western blot analysis as described in
the methods section. The SP1 antibody used is mentioned in the methods section. Protein was also used to measure Aβ1−40 by a sandwich
ELISA assay (IBL, Japan). Four time points are shown. Representative blots are shown in insets for western analysis. A) Relative AβPP levels;
B) Relative SP1 levels; C) Aβ40 levels. Each data point in the curve is the mean + SEM (n = 3 animals). “∗” denotes significant difference
between Aβ levels at PND 630 as compared to PND 365. Western blot results were normalized to β-actin signal.
gene regulatory variation should, likewise, be expected
between rodent model systems and human AD.
SP1 promoter sequence homologies versus human
Promoter homology comparison in a 50 bp window
(up to 4 kb upstream of the +1 TSS) of SP1 (Fig. 7A)
produced two distinct running profiles when compar-
ing mouse vs. human and monkey vs. human. Homol-
ogy between mouse and human sequences was most-
ly between 25% and 50% from −4000 to −1600 on
the human sequence, counting the TSS as +1, when it
rose to around 75% from −1400 to −100 (human se-
quence numbering). From −100 through the 5’-UTR
(+1 to+101), homologywas between 90% and 100%.
When comparing monkey to human SP1 5’-flanking
sequences (Fig. 7B), there was no region of homology
between −4000 and −3709 on the human sequence.
From −3709 to −2450, homology was 85%-100%. A
sharp drop in homology occurred at −2450 to −1950,
where homologydropped to 25%, rose to 75% and then
dropped back to 25%. From −1950 to the end of the
5’-UTR (+101), homology of between 85% and 100%
resumed.
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Fig. 3. Lifespan mRNA expression changes in AD related genes (SP1, AβPP, BACE1) in the primate brain cortex. Relative quantification was
measured by using 7500 Real-Time PCR System (Applied Biosystems, CA) with GAPDH serving as the endogenous control. Three time points
are shown. A) Relative AβPP mRNA. B) Relative SP1 mRNA. C) Relative BACE1 mRNA. Each data point in the curve is the mean + SEM
(n = 3 monkeys). “*” denotes significant difference for SP1 or AβPP mRNA time point when compared to 12 years age.
Unique transcription factor binding sites predicted in
SP1 promoter of mouse versus primate (monkey and
human)
We used the human, monkey, and mouse SP1 pro-
moter sequences, 4 kb upstreamof the+1TSS, to probe
the transcription factor database included inMatInspec-
tor (v. 7.7). Hundreds of sites were shared between
both rodents and primates (data not shown). However,
when the output was screened to include only those
sites that were unique by transcription factor and tran-
scription factor family, 18 different transcription factor
families, each represented by a single factor, remained
(Table 2). For mouse, the families were represented
by transcription factors activator protein 2 (AP2), au-
toimmune regulatory element binding factor (AIRE), a
barbiturate-inducible element (BARBIE), downstream
immunoglobulin control element, critical for B cell ac-
tivity and specificity (DICE), GTF2I-like repeat 4 of
GTF3 (GTF3R4), and Nuclear DEAF-1-related protein
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Fig. 4. Lifespan profile of AD related proteins (AβPP, SP1, and Aβ) in the primate brain. Protein from cortical tissue of Cynomolgus primate was
isolated and probed with 22C11 AβPP N-terminus antibody with SDS-PAGE western blot analysis as described in the text. The SP1 antibody
used is mentioned in the methods section. Protein was also used to measure Aβ1−40 using an ELISA assay (IBL, Japan). A) Relative AβPP
protein signal; B) Relative SP1 signal; C. Aβ40 levels. Each data point in the curve is the mean + SEM (n = 3 monkeys). Western blot results
were normalized to β-actin signal. Representative blots are shown in insets for western analysis.
(NUDR).
Transcription factor families unique to the primate
(human and monkey) sequences were represented by
the specific factors of amino acid response element
(AARE), T-box transcription factor 5 (TBX5), kaiso (a
zinc-finger transcription factor), the factor for Friend
leukemia integration site 1 (FLI), hypoxia inducible
factor 1 (HIF1), hypermethylated in cancer 1 (HIC1),
transcription factor 11 (TCF11), myocyte expression
factor 3 (MEF3), Neuron-restrictive silencer factor
(NSRF), Pancreas transcription factor 1 (PTF1), the
Notch-associated factor RBPJκ (RBPJκ), and THAP
domain containing, apoptosis associated protein 1
(THAP1).
Regulatory factor and miRNA binding sites in the
5’-UTR of human, monkey, and mouse AβPP
To assess potential pathways whereby differences in
posttranscriptional regulation of primate vs. murid ro-
dent AβPP may operate, the 5’- and 3’-UTRs of the hu-
man, cynomolgusmonkey, andmouseAβPP genewere
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Fig. 5. Lifespan profile of BACE1 secretase activity in the mouse and primate brain. Protein from cortical tissue of mouse and Cynomolgus
primate was isolated and BACE1 activity measured using the BACE1 activity assay kit (R&D Systems, Inc., MN). The y–axis reports raw
intensity numbers from fluorescence spectrophotometry. A) BACE1 activity in mice at six time points. B) BACE1 activity in monkeys at three
time points. Each data point in the curve is the mean + SEM (n = 3 animals).
analyzed via the RegRNA utility. In addition, some
microRNA (miRNA) sites determined were redundant
homologies, since both the human and mouse miRNA
databases were used to search these sequences. In the
5’-UTRs (Table 3), we noticed that all three species
had terminal oligopyrimidine tracts (TOP), although
the mouse sequence had only one while the human and
monkey sequences had three. Furthermore, three dif-
ferent human miRNA homology sites (has-miR-346,
502, 504) were found in both monkey and human se-
quences but not in the mouse (along with three sites for
the homologousmouse miRNAs). One mouse miRNA
homology site (mmu-miR-328)was found in themouse
sequence (homologous to a single human miRNA) but
neither in monkey nor human.
Regulatory sites in 3’-UTR in different species
Examining the 3’-UTR sequences of human, cyno-
molgus monkey, and mouse also revealed potentially
important differences in regulatory motifs (Table 4).
All three sequences had the AβPPmRNA stability con-
trol element (AβPP SCE). However, the mouse se-
quence alone possessed (two copies of) the cytoplasmic
polyadenylation element (CPE). While all sequences
had at least two copies of the gamma interferon ac-
tivated inhibitor of ceruloplasmin mRNA translation
(GAIT) motif, the human and monkey sequences had
five more or four more such sites, respectively, than did
the mouse. Similarly, human and monkey sequences
had more selenocysteine insertion sequence (SECIS)
motifs than did the mouse. The major difference no-
ticed in regard to miRNA homology sites was that hu-
man and monkey sequences shared five (has-miR-17-
5p, 20b, 106b, 483, 485-5p) human sites (with five ho-
mologous mouse miRNAs) found in mouse, while the
mouse sequence had one uniquemouse miRNA (mmu-
miR-99b) site (with a homologous human miRNA).
DISCUSSION
We undertook our study specifically to test a critical
unspoken assumption in the field of AD research, that
conventional rodent animal models can be presumed to
be sufficiently similar to humans that results from the
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Fig. 6. Genomic homology of mouse SP1 and AβPP with human SP1 and AβPP. Genomic reference sequences for human SP1 and AβPP were
used to BLAST the mouse reference genomic assembly as described in the text. Diagram represents coverage of homological regions over entire
genomic sequences. Colors indicate percent homology as indicated by keys on figure. A) Homology of mouse SP1 versus human SP1. Numbers
along alignment indicate position in human chromosomal genomic sequence. B) Homology of mouse AβPP versus human AβPP. Numbers
along alignment indicate position in human reference gene sequence [81]. C) Homology of monkey SP1 versus human SP1. Numbers along
alignment indicate position in human chromosomal genomic sequence. D) Homology of monkey AβPP versus human AβPP. Numbers along
alignment indicate position in human reference gene sequence [81].
animal models can be “linearly applied” to the human
condition. We, therefore, compared levels of proteins
shown to be critical forADetiology betweenmurine ro-
dents and primates, specifically to see howmuch actual
similarity existed for the expression of these proteins
between rodent models and primates (which would in-
clude humans).
Animal disease models are not necessarily “non-
reactive vessels” – the substrate species has its own nor-
mal expression patterns and pathways for etiologically
interesting genes. These patterns and pathways may
or may not significantly resemble those of the ultimate
target species, which for AD would be humans. It is
not knownwhether or not “normal” expression patterns
do or do not interact with ADmodels imposed onmice.
An indispensible step in learning whether or not the
mouse functions more as a “vessel” or as an “environ-
ment” for AD models is to understand lifetime non-
diseased expression patterns of AD-associated genes.
This understanding is enlarged in the context of trans-
lation of animal results to human subjects by compar-
ing these patterns between mice and primates that are,
presumably, more closely related to humans.
The single most important risk factor in the etiology
of AD is age. The majority of research within the field
“short-circuits” this risk factor by utilizing transfected
cell cultures and short-lived natural or transgenic mod-
els. These “time-compressed” models of AD have not
been evaluated by comparison to actual aging, partic-
ularly not for comparison of non-pathological lifespan
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Fig. 7. Homology of mouse and monkey SP1 promoter sequences with human SP1 sequence. Sequences of 4 kb length upstream of the +1 TSS
were taken from genomic reference sequences for mouse, rhesus monkey, and human SP1, and ClustalX was used to align each of the monkey and
mouse sequences to the human. Diagram represents percent homology of each non-human sequence with human sequence in a 50-bp window.
A) Homology of mouse SP1 promoter versus human SP1 promoter. B) Homology of monkey SP1 promoter versus human SP1 promoter.
expression of genes and proteins associated with AD,
such as AβPP, BACE1, and Aβ between plaque form-
ing (primate) and non-plaque forming (rodent) species.
In this study, constitutive AβPP and SP1 mRNA ex-
pression mirror each other across the rodent lifespan
and thus either gene could be a biomarker for the oth-
er. These findings are consistent with previous siRNA
studies, which showed a dramatic drop in AβPP pro-
moter activity, if SP1 levels are depleted [26] and with
other surveys of AβPP and SP1 mRNA [40–42]. Im-
munohistochemical studies have shown that AβPP and
SP1 co-localize to neurons and have a similar distribu-
tion in the brain [43]. These lifetime signatures estab-
lish SP1 as a partner transcription factor that controls
AβPP expression across the lifespan.
BACE1 mouse mRNA levels remained unchanged
(data not shown). This may indicate that, in mice,
SP1 does not drive BACE1 mRNA expression in the
same manner as does AβPP. Other studies have shown
that, even when AβPP is transgenically upregulated,
BACE1 mRNA levels do not alter significantly at dif-
ferent ages [44]. BACE1 overexpression with elevated
mRNA level was only seen in genomic BACE1 trans-
genic mice [45].
In primates, themRNAexpression ofAβPP,BACE1,
and SP1 showed the same trend among all age groups.
Higher levels of SP1mRNA expressionwere accompa-
nied by greater AβPP and BACE1 mRNA expression,
and vice-versa. This would not be inconsistent with
SP1 coordinately regulating both AβPP and BACE1
gene expression in primates. However, there was no
elevation of mRNA expression for the genes in old age,
instead, mRNA levels for those genes decreased in the
oldest age group of monkeys.
Several studies have reported age related brain
AβPP mRNA changes in cynomolgus monkeys, nor-
mal humans, and AD patients. A primate study [46]
showed unchanged mRNA levels of AβPP751 and
AβPP695 in cortical regions in the aged group in com-
parison to the young group, but expression in tha-
lamus was significantly increased with a decreased
AβPP695/AβPP751 ratio in aged monkeys. Another
report found no differential expression of alternatively
spliced AβPP mRNA transcripts in AD cases or aged
monkeys [47]. A study reported that the mRNA ra-
tioAβPP770+751/AβPP695 increasedwith age in AD
patients [48], while another study found expression of
majorAβPPmRNA in neocortex declined as a function
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Table 2
Unique transcription factor family sites in SP1 promoters of human and monkey vs. mouse
Factor Family Human Monkey Mouse
AARE AARE binding factors −3830,
−2743,
−1833
−3050,
−2132
AP2 Activator protein 2 −1232,
−1232
AIRE Autoimmune regulatory element binding factor −3472,
−3308,
−2044,
−1476
BARBIE Barbiturate-inducible element box from pro+eukaryotic genes −2272,
−1707, −732,
−671
TBX5 Brachyury gene, mesoderm developmental factor −3920,−823 −806
KAISO BTB/POZ (broad complex, TramTrack, Bric a` brac/pox viruses and
zinc fingers) transcription factor
−1970 −2270
DICE Downstream Immunoglobulin Control Element, critical for B cell ac-
tivity and specificity
−1636
GTF3R4 GTF2I repeat domain–containing factors −58
NUDR Homolog to deformed epidermal autoregulatory factor-1 from D.
melanogaster
−872, −766
FLI Human and murine ETS1 factors −313 −294
HIF1 Hypoxia inducible factor, bHLH/PAS protein family −1877,−330 −3910
HIC1 Krueppel–like C2H2 zinc finger factors hypermethylated in cancer −482 −463
TCF11 MAF and AP1 related factors −364 −345
MEF3 MEF3 binding sites −2731 −3834,
−3204
NRSF Neuron-restrictive silencer factor −2820, 48 67
PTF1 Pancreas transcription factor 1, heterotrimeric transcription factor −1281 −1258
RBPJκ Notch–associated RBPJ–κ −3977 −3646,
−3635
THAP1 THAP domain containing protein −2799 −3106
of age in both AD and control cases [49]. On the other
hand, there was a report of no alteration of total AβPP
mRNA as well as AβPP with Kunitz protease inhibitor
(KPI) in a wide range of age group of control human
subjects [50]. These contradictory results are probably
caused by the methods for studying mRNA used by
different studies. For example, solution hybridization-
RNase protection assay [48,50] is more sensitive and
quantitative than the Northern blot analysis utilized by
another group [49]. Moreover, several factors, such as
gender, postmortem interval, and brain pHwould affect
the quantification of mRNA when postmortem brain
tissues are utilized [51].
In mice, AβPP and SP1 gene expression and their
protein productswere elevated late in life; however, Aβ
levels declined in old age. In monkeys, SP1, BACE1,
andAβPPmRNA expression declined in old age, while
their protein products, as well as Aβ levels, rose. In
rodents, Aβ levels in old age do not appear to be main-
tained by the transcriptional or translational status of
the AβPP gene but instead by enhanced degradation
and clearance. In primates, there is an inverse relation-
ship between AβPP and SP1 mRNA levels and their
Table 3
Presence of selected motifs in AβPP 5’-UTR mRNA
from human, monkey, and mouse
Motif Human Monkey Mouse
TSSa 1 1 1
AUG 148 144 146
TOPb 6, 52, 131 5, 51, 127 5
hsac-miR-324-3p 54 44
hsa-miR-328 29
hsa-miR-346 69 62
hsa-miR-502 71 70
hsa-miR-504 123 119
mmud-miR-296 33 35 35
mmu-miR-324-3p 54 44
mmu-miR-328 29
Mmu-miR-346 63 62
Sites unique to mouse are in boldface. Sites found in
monkey and human but not mouse are italic.
a+1 Transcription Start Site.
bTerminal Oligopyrimidine Tract.
cHomo sapiens, human.
dMus musculus, mouse.
corresponding protein products, as well as Aβ levels.
While the specific mechanism of this disparity is not
apparent, it suggests that enhanced translational effi-
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Table 4
Presence of selected motifs in AβPP 3’-UTR mRNA from human,
monkey, and mouse
Motif Human Monkey Mouse
stop codon 2458a 2229a 2231b
AβPP SCEc 2659 2435 2445
CPEd 2931, 2941
GAITe 2704, 2787, 3013, 2291, 2562,
3096, 3130, 3392, 2788, 2901,
3397 2938 2580, 2638
SECISf 2361, 2362,
3478, 3479 2365 2567
hsa–miR–17–5p 3155 2926
hsa–miR–20b 3156 2927
hsa–miR–99b 2960
hsa–miR–106b 3158 2929
hsa–miR–483 3181 2952
hsa–miR–485–5p 2464 2235
mmu–miR–17–5p 3155 2926
mmu–miR–20a 3156 2927
mmu–miR–99b 2960
mmu–miR–106a 3157 2928
mmu–miR–106b 3158 2929
mmu–miR–485–5p 2464 2235
Sites unique to mouse are in boldface. Sites found in monkey and
human but not mouse are italic.
a“UAG”.
b“UAA”.
cAmyloid-β Protein Precursor mRNA Stability Control Element.
dCytoplasmic Polyadenylation Element.
eGamma Interferon Activated Inhibitor of Ceruloplasmin mRNA
Translation.
fSelenocysteine Insertion Sequence–type 1.
ciency or reduced protein degradation may account for
a rise in AβPP consequently elevating Aβ levels in
primates.
We found that BACE1 activity remains practical-
ly unchanged across the entire adult lifespan of mice
and has a non-significant decrease in monkeys. Thus,
BACE1 activity does not appear to mirrorAβ levels nor
is it influenced by AβPP levels. Neither does it appear
to match the decline in BACE1 mRNA levels in mon-
keys. We must note that currently available β-secretase
activity assays are not necessarily specific for BACE1
if used on tissue extracts instead of purified BACE1
protein. However, of the alternatives, BACE1 is the
primary β-secretase [29] and is likely to be responsible
for most of the measured activity and changes in this
activity.
We did note apparently dramatic changes between
postnatal days 5 to 20 in levels ofmouse SP1 andAβPP
mRNA, inmouseAβPP, and inmouseAβ. While these
results may help illuminate regulation of these genes
in mouse, we have previously published in greater de-
tail on developmental expression of such genes in ro-
dents [26,52,53].
Given the differences we found in AβPP mRNA and
protein levels between mouse and monkey, we exam-
ined homology at the genomic level. Rhesus monkey
and human AβPP promoter sequences up to 4 kb have
previously been shown to have high (> 90%) homol-
ogy [54]. The full-length (∼300 kb) monkey genomic
sequence preserved approximately 90%homologywith
the human reference AβPP genomic sequence, while
mouse had no more than 3% homological regions. Re-
spective SP1 genomic sequences’ homology compari-
son with human showed that monkey sequence had up
to 63% homology coverage versus 19% for mouse ver-
sus human. The majority of non-homologous regions
were intronic. Intronic regulation of mRNA levels has
been well demonstrated [55,56]. The large differences
between respective mouse and monkey genomic SP1
homologies to human likely contribute to differences
in mRNA levels for this transcription factor, although
greater differences in AβPP homologies do not seem
to alter tight transcriptional control of AβPP by SP1.
We also examined the promoters of monkey and
mouse SP1 genes for structural differences versus the
human SP1 gene and determined very high homolo-
gy (> 90%) between monkey and human over most
of 4 kb upstream of the +1 TSS, while mouse and
human homology remained around 75% for most of
this length. In addition, the primate SP1 promoter se-
quences were predicted to have several transcription
factor binding sites absent in the mouse sequence. Of
particular interest is the presence or absence ofAP2 and
HIF1 sites. AP2 has been implicated in regulation of
the BACE1 gene promoter [57]. HIF1 activity has been
linked to neuroprotection against Aβ [58] but paradox-
ically upregulates BACE1 and results in greater gener-
ation of Aβ [59]. In addition, the presence of RBPJκ
sites may be pathogenically interesting, given that the
role of transcription factor in notch-associated inhibi-
tion of apoptosis [60]. NRSF is a potent repressor of
transcription of neuron-specific genes in non-neuronal
cells [61]. TBX5 is a developmental regulator that in-
duces apoptosis [62]. THAP1 is a nuclear proapoptotic
factor [63]. Factors such as NRSF, HIF1, or RBPJκ
could function to downregulate SP1 in healthy neu-
ronal tissue, while factors such as THAP1 could be ac-
tive during apoptotic or pathological states, such as in
AD. These interactions would not be possible with the
mouse SP1 promoter, given that the sites are not avail-
able on the mouse sequence. Beyond the differences
in predicted transcription factor binding sites, intronic
regulation of hnRNA processingmay also play a role in
the differences observed between mouse and monkey
SP1 mRNA levels.
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Upon examining Aβ peptide levels, we noted that
in neither species did the peptide levels closely fol-
low AβPP mRNA levels in the aging paradigm stud-
ied herein. We, therefore, examined differences in the
5’- and 3’-UTRs of mouse versus cynomolgusmonkey
AβPP mRNA.We determined that the mouse sequence
lacked two of three TOP motifs found in the human
and monkey sequences. TOP presumably functions for
translational repression [64]. The presence of multiple
TOP sites in primate sequences versus a single TOP site
in mousemay indicate that, early in life, primate AβPP
mRNA translation may be more strongly suppressed
than mouse, and some mechanism later operates on the
primate 5’-UTR to overcome this suppression. One
such potential mechanismmay involve the absence of a
“CAGA” box within the 5’-UTR of mice and rats. This
“CAGA” box is present in theAβPP 5’-UTR sequences
of plaque-formingmammalian species [18] and resides
in a region of the AβPP 5’-UTR that has been shown
to be targeted by the potential anti-AD drug, phenser-
ine [65,66]. Activity of miRNA on the 5’-UTR in reg-
ulation of translation may also explain differences in
mouse versus monkey protein levels. It has been re-
cently shown that miRNA can be active via the 5’-UTR
in repression of mRNA translation [67].
Our examination of the 3’-UTR has also suggested
avenues to explore for differential mRNA regulation.
Two CPE sites were present in mouse mRNA versus
absent in primate. This motif stabilizes mRNA and in-
creases posttranscriptional expression. However, it on-
ly does so up through the blastoderm stage [68]. AβPP
and its Aβ product have developmental functions that
have only been partially elucidated [69,70]. It is pos-
sible that murid rodents have evolved a specific means
of early-developmental regulation of AβPP translation
via the 3’-UTR. However, in addition to CPE, we also
determined that the human and monkey AβPP 3’-UTR
sequences had three times as manyGAITmotifs (an in-
hibitor of mRNA translation) as didmouse. This points
toward aging-related derepression of translation to ex-
plain increasing levels of AβPP protein in primates.
However, in addition to these differences, mouseAβPP
3’-UTR had one unique miRNA binding site, which
may repress mouse AβPP translation, via 3’-UTR re-
pression by miRNA binding [67]. Alternatively, the
miRNA sites that occur in primate but not mouse se-
quences may function to activate primate AβPP mR-
NA translation, as has been determined to occur for
tumor necrosis factor alpha [71]. Direct confirmation
of the active status of these sites in the AβPP mRNAs
would determine which mechanism or mechanisms are
actually functioning for this particular gene.
With aging, other factorsmay additionally contribute
to the amyloidogenic pathway. A recent study [72]
with normally aging human beings found the non-
amyloidogenicα-secretase pathway declined due to ag-
ing, and, while β-secretase activity was increased, lev-
els of Aβ40 and Aβ42 did not change with age. Since
that study onlymeasured the insoluble form of Aβ, this
result did not represent the whole Aβ pool. Aging is
also a crucial factor resulting in reduced Aβ clearance
by degrading enzymes. Aging rats showed much less
elimination of Aβ1−40 from brain to peripheral circu-
lation than young rats [73].
In addition to aging-related factors, species-intrinsic
differences also need to be considered, such as those
we have recently demonstrated in our analysis of the
human apolipoprotein E (APOE) gene promoter in
human-origin versus rodent-origin cell lines and nucle-
ar extracts [74].
Regarding the aforementioned results and their in-
terpretations, the overall mouse mRNA data is simi-
lar to that performed in an independent set of rats pre-
viously published [26]. An mRNA analysis of mon-
keys produced similar readings, as previously pub-
lished by us for aged monkeys [75]. Confidence is al-
so raised in the rodent protein data through measure-
ment at multiple intermediate ages. The data points
on the curves presented were derived from 3–4 an-
imals. When considering these profiles, one may
keep in mind that the overall signature profiles are
more important than individual points on the curve.
Similarity and contrast of the lifespan expression of
amyloid pathway genes and their products between
amyloid-producing species (cynomolgus monkey) and
non-amyloid species (mouse) are the major focus of
the present work. Alternative explanations may suffice
for the observed differences between mouse and mon-
key in AβPP expression and Aβ metabolism. While
both populations were maintained in laboratory con-
ditions, these conditions could not, of course, have
been identical. Each species has different nutrition-
al requirements, requiring that their feed differ from
each other. This introduces the potential for dietary
effects on AβPP expression, similar to those seen for
the PSEN1 gene [76]. Epigenetic effects also cannot
be ruled out [77]. Likewise, the great divergence in
overall lifespan raises the possibility of a fundamental
difference of aging programs that is not limited to SP1,
AβPP, or BACE1. That is to say, differences seen in the
expression and activity of these genes’ products may
actually reflect a deeper and more profound difference
between the two species, altogether, one that raises the
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Table 5
Summary of mRNA expression, protein or peptide levels, and enzymatic activity, monkey
versus mouse
Monkey Mouse
Gene mRNA Protein/ Peptide/Activity mRNA Protein/Peptide/Activity
SP1 ↓ ↑ ↑ ↑
AβPP ↓ ↑ ↑ ↑
BACE1 ↓ ↓ nca nc
Aβ ↑ ↓
aNo change.
Fig. 8. Relationship between mRNA and protein product levels of selected AD–related genes in mouse versus monkey. Diagram illustrates levels
of mRNA versus protein product levels of SP1 and AβPP in animal models studied. Solid line indicates mRNA levels over lifespan while dashed
line indicates protein levels over lifespan. For each species, mRNA and protein levels diverge from each other in later life, albeit in opposite
directions when comparing species to species. A) Mouse mRNA and protein levels. B) Monkey mRNA and protein levels.
question of applicability of results from one model to
another.
In a broader context, the present work underscores
the importance of studying the regulation of gene ex-
pression in relation to the disease process. Structural
similarity of gene coding sequences is often taken as
a strong indicator of the suitability of a model system,
especially when a model is transgenic, since it has the
exact human coding sequence. Experience has shown
that such models have limits. Notably, a natural mod-
el considered as close as 99% homologous to humans,
such as the chimpanzee, does not afford a 99% level
of gene-based pathogenic functional similarity. Fun-
damental differences in gene regulation and interaction
may play a more important role in determining differ-
ences than primary DNA sequence [78]. These regu-
latory differences could likewise be significantly influ-
enced by environmental factors, such as diet andmetals
at the very early stage of development and, important-
ly, could be manifested later in the life after prolonged
latency, as explained in a recently proposed ‘LEARn’
model (Latent Early-life Associated Regulation) [74]
and discussed for the somatic epitype [79].
In summary, we have examined the lifetime profiles
of intermediates in the amyloid cascade pathway in both
non-plaque-forming rodents and plaque-forming pri-
mates (Table 5). We found that the expression pattern
of AβPP mRNAmirrors that of the transcription factor
SP1, and thus SP1 may be a lifelong regulator of the
AβPP gene. We also noted that in both species, there
is a complex relationship between AβPP mRNA ex-
pression and AβPP protein levels. Furthermore, in non
plaque-forming rodents, Aβ did not accumulate in the
brainwith aging; however, in plaque-formingprimates,
both AβPP protein and Aβ accumulated. These find-
ings are summarized diagrammatically in Fig. 8. Pro-
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teolytic enzyme activity does not match the production
levels of Aβ. The discrepancy between AβPP mRNA
and AβPP protein as well as Aβ in both species may
be due to different nucleic acid structure-based mecha-
nisms, as our comparisons of genomic and mRNA se-
quences suggest. In mice, posttranslational pathways
related to Aβ clearance or degradation appear to pre-
vent any accumulation of Aβ levels. On the other hand,
enhanced translational efficiency or decreased AβPP
degradation may lead to an accumulation of AβPP and
Aβ in non-human primates. Posttranslational regula-
tion and AβPP protein metabolism may also play a
crucial role in amyloidogenesis.
Our results point toward the need to carefully and ra-
tionally select animal models, even transgenic models,
to understand fundamental molecular mechanisms of
human disease. Differential regulation of “pathogenic”
genes points toward the need for models that preserve a
similar regulatory milieu to the ultimate target species
(in the case of AD, human). Transgenic models may
be able to fulfill this need, but each level of regu-
lation (transcriptional, translational, posttranslational)
requires more transgenes be combined, and raises the
possibility that the transgenes, themselves, may be sub-
ject to potentially important species–differentiated reg-
ulation.
The current prospect for mouse models of AD is
mixed, with much work done on animals transgenic for
mutant AβPP, mutant PSEN1, and the two combined.
Likewise, there are also knockouts for AβPP, BACE1,
MAPT, and other genes implicated in AD. Most of the
transgenic lines use a “strong” promoter specifically to
ensure high production of the protein of interest. This
practice has also meant that studying possible contri-
butions of gene regulation to etiology may have been
sidestepped, entirely. Recently, mouse lines have be-
gun to be developed that are transgenic for both the
coding sequence and promoter of AD-related genes of
interest, such as tau. It should be noted that work with
the promoters of the AD-associated gene APOE for
mouse and human has revealed that the human pro-
moter can have different responses in rodent-origin cell
lines and nuclear extracts than in cells and extracts of
human origin [74]. Thus, even though improvements
are likely in rodent models, there may always be an
inherent limitation to the practice. The authors do not
wish this cautionary statement regarding mouse mod-
els to be taken as an indictment of animal modeling of
AD altogether. This work raises the question of the ap-
plicability of a particular model species toward transla-
tion of AD research to humans. Even though there are
stark contrasts between mouse and primate expression
patterns, other rodent species, such as guinea pig [80],
could serve as useful non-transgenic models for AβPP
processing and expression.
ACKNOWLEDGMENTS
This research was supported by the Intramural Re-
search Program of the National Institutes of Health
(NIH), National Institute of Environmental Health
Sciences (NIEHS) and by grants (ES013022 and
AG027246) from the NIH awarded to NHZ. The re-
search core facility was funded (P20RR016457) by
the National Center for Research Resources (NCRR),
a component of NIH. Work at DKL’s laboratory was
funded by grants from the Alzheimer’s Association
and National Institute on Aging, NIH (AG18379 and
AG18884).
Authors’ disclosures available online (http://www.j-
alz.com/disclosures/view.php?id=21).
REFERENCES
[1] Tanzi RE, Bertram L (2008) Alzheimer’s disease: The latest
suspect. Nature 454, 706-708.
[2] Selkoe DJ (1991) Amyloid protein and Alzheimer’s disease.
Scientific American 265, 68-66, 78.
[3] Sambamurti K, Suram A, Venugopal C, Prakasam A, Zhou
Y, Lahiri DK, Greig NH (2006) A partial failure of mem-
brane protein turnover may cause Alzheimer’s disease: a new
hypothesis. Curr Alzheimer Res 3, 81-90.
[4] Lahiri DK, Farlow MR, Sambamurti K, Greig NH, Giacobini
E, Schneider LS (2003) A critical analysis of new molecular
targets and strategies for drug developments in Alzheimer’s
disease. Curr Drug Targets 4, 97-112.
[5] Goedert M, Spillantini MG (2006) A century of Alzheimer’s
disease. Science 314, 777-781.
[6] Maslow K (2008) 2008 Alzheimer’s disease facts and figures.
Alzheimers Dement 4, 110-133.
[7] Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE,
Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance
MA (1993) Gene dose of apolipoprotein E type 4 allele and
the risk of Alzheimer’s disease in late onset families. Science
261, 921-923.
[8] Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop
PH, Pericak-VanceMA, JooSH,RosiBL,Gusella JF,Crapper-
MacLachlan DR, Alberts MJ, et al. (1993) Association of
apolipoprotein E allele epsilon 4 with late-onset familial and
sporadic Alzheimer’s disease. Neurology 43, 1467-1472.
[9] Evans DA, Beckett LA, Field TS, Feng L, Albert MS, Bennett
DA, Tycko B, Mayeux R (1997) Apolipoprotein E epsilon4
and incidence ofAlzheimer disease in a community population
of older persons. JAMA 277, 822-824.
[10] Price DL, Sisodia SS (1998) Mutant genes in familial
Alzheimer’s disease and transgenic models. Ann Rev Neurosci
21, 479-505.
228 R. Dosunmu et al. / Lifespan Profiles of Alzheimer’s Disease-Associated Genes
[11] Fukuchi K, Ogburn CE, Smith AC, Kunkel DD, Furlong CE,
Deeb SS, Nochlin D, Sumi SM,Martin GM (1993) Transgenic
animal models for Alzheimer’s disease. Ann N Y Acad Sci 695,
217-223.
[12] Wirak DO, Bayney R, Ramabhadran TV, Fracasso RP, Hart
JT, Hauer PE, Hsiau P, Pekar SK, Scangos GA, Trapp BD,
et al. (1991) Deposits of amyloid beta protein in the central
nervous system of transgenic mice. Science 253, 323-325.
[13] Kawabata S, Higgins GA, Gordon JW (1991) Amyloid
plaques, neurofibrillary tangles and neuronal loss in brains
of transgenic mice overexpressing a C-terminal fragment of
human amyloid precursor protein. Nature 354, 476-478.
[14] Games D, Adams D, Alessandrini R, Barbour R, Berthelette
P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie
F, et al. (1995) Alzheimer-type neuropathology in transgenic
mice overexpressing V717F beta-amyloid precursor protein.
Nature 373, 523-527.
[15] Jankowsky JL,Younkin LH, Gonzales V, Fadale DJ, Slunt HH,
Lester HA, Younkin SG, Borchelt DR (2007) Rodent A beta
modulates the solubility and distribution of amyloid deposits
in transgenic mice. J Biol Chem 282, 22707-22720.
[16] Podlisny MB, Tolan DR, Selkoe DJ (1991) Homology of the
amyloid beta protein precursor in monkey and human supports
a primate model for beta amyloidosis in Alzheimer’s disease.
Am J Pathol 138, 1423-1435.
[17] Fung J, Frost D, Chakrabartty A, McLaurin J (2004) Interac-
tion of human and mouse Abeta peptides. J Neurochem 91,
1398-1403.
[18] Maloney B, Ge YW, Greig N, Lahiri DK (2004) Presence of a
CAGA box in the APP gene unique to amyloid plaque-forming
species and absent in all APLP-1/2 genes: implications in
Alzheimer’s disease. FASEB J 18, 1288-1290.
[19] La Fauci G, Lahiri DK, Salton SR, Robakis NK (1989) Char-
acterization of the 5’-end region and the first two exons of the
beta-protein precursor gene. Biochem Biophys Res Commun
159, 297-304.
[20] Salbaum JM, Weidemann A, Lemaire HG, Masters CL,
Beyreuther K (1988) The promoter of Alzheimer’s disease
amyloid A4 precursor gene. EMBO J 7, 2807-2813.
[21] Pollwein P, Masters CL, Beyreuther K (1992) The expression
of the amyloid precursor protein (APP) is regulated by two
GC-elements in the promoter. Nucleic Acids Res 20, 63-68.
[22] HoffmanPW,Chernak JM (1995)DNAbinding and regulatory
effects of transcription factors SP1 and USF at the rat amyloid
precursor protein gene promoter. Nucleic Acids Res 23, 2229-
2235.
[23] Docagne F, Gabriel C, Lebeurrier N, Lesne S, Hommet
Y, Plawinski L, Mackenzie ET, Vivien D (2004) Sp1 and
Smad transcription factors co-operate to mediate TGF-beta-
dependent activation of amyloid-beta precursor protein gene
transcription. Biochem J 383, 393-399.
[24] Kadonaga JT, Carner KR, Masiarz FR, Tjian R (1987) Isola-
tion of cDNA encoding transcription factor Sp1 and functional
analysis of the DNA binding domain. Cell 51, 1079-1090.
[25] Hagen G, Dennig J, Preiss A, Beato M, Suske G (1995) Func-
tional analyses of the transcription factor Sp4 reveal properties
distinct from Sp1 and Sp3. J Biol Chem 270, 24989-24994.
[26] Basha MR, Wei W, Bakheet SA, Benitez N, Siddiqi HK, Ge
YW, Lahiri DK, Zawia NH (2005) The fetal basis of amy-
loidogenesis: exposure to lead and latent overexpression of
amyloid precursor protein and beta-amyloid in the aging brain.
J Neurosci 25, 823-829.
[27] Santpere G, Nieto M, Puig B, Ferrer I (2006) Abnormal
Sp1 transcription factor expression in Alzheimer disease and
tauopathies. Neurosci Lett 397, 30-34.
[28] Christensen MA, Zhou W, Qing H, Lehman A, Philipsen S,
SongW (2004) Transcriptional regulation of BACE1, the beta-
amyloid precursor protein beta-secretase, by Sp1. Mol Cell
Biol 24, 865-874.
[29] Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price
DL, Wong PC (2001) BACE1 is the major beta-secretase for
generation of Abeta peptides by neurons. Nature Neurosci 4,
233-234.
[30] Heicklen-Klein A, Ginzburg I (2000) Tau promoter confers
neuronal specificity and binds Sp1 and AP-2. J Neurochem 75,
1408-1418.
[31] von Strauss E, Viitanen M, De Ronchi D, Winblad B,
Fratiglioni L (1999) Aging and the occurrence of dementia:
findings from a population-based cohort with a large sample
of nonagenarians. Arch Neurol 56, 587-592.
[32] Sani S, Traul D, Klink A, Niaraki N, Gonzalo-Ruiz A, Wu
CK, Geula C (2003) Distribution, progression and chemical
composition of cortical amyloid-beta deposits in aged rhesus
monkeys: similarities to the human. Acta Neuropathol (Berl)
105, 145-156.
[33] Marvanova M, Menager J, Bezard E, Bontrop RE, Pradier L,
Wong G (2003) Microarray analysis of nonhuman primates:
validation of experimental models in neurological disorders.
FASEB J 17, 929-931.
[34] Nagahara AH, Bernot T, Tuszynski MH (2009) Age-related
cognitive deficits in rhesus monkeys mirror human deficits on
an automated test battery. Neurobiol Aging, in press.
[35] Wu J, Basha MR, Brock B, Cox DP, Cardozo-Pelaez F,
McPherson CA, Harry J, Rice DC,Maloney B, Chen D, Lahiri
DK, Zawia NH (2008) Alzheimer’s disease (AD)-like pathol-
ogy in aged monkeys after infantile exposure to environmen-
tal metal lead (Pb): evidence for a developmental origin and
environmental link for AD. J Neurosci 28, 3-9.
[36] Morishima-Kawashima M, Oshima N, Ogata H, Yamaguchi
H, Yoshimura M, Sugihara S, Ihara Y (2000) Effect of
apolipoprotein E allele epsilon4 on the initial phase of amyloid
beta-protein accumulation in the human brain. Am J Pathol
157, 2093-2099.
[37] Jeanmougin F, Thompson JD, Gouy M, Higgins DG, Gibson
TJ (1998) Multiple sequence alignment with Clustal X. Trends
Biochem Sci 23, 403-405.
[38] Quandt K, Frech K, Karas H, Wingender E, Werner T (1995)
MatInd and MatInspector: new fast and versatile tools for
detection of consensus matches in nucleotide sequence data.
Nucleic Acids Res 23, 4878-4884.
[39] HuangHY,ChienCH, JenKH,HuangHD (2006) RegRNA: an
integrated web server for identifying regulatory RNA motifs
and elements. Nucleic Acids Res 34, W429-434.
[40] Apelt J, Bigl M, Wunderlich P, Schliebs R (2004) Aging-
related increase in oxidative stress correlates with develop-
mental pattern of beta-secretase activity and beta-amyloid
plaque formation in transgenic Tg2576 mice with Alzheimer-
like pathology. Int J Devel Neurosci 22, 475-484.
[41] Rossner S, Sastre M, Bourne K, Lichtenthaler SF (2006) Tran-
scriptional and translational regulation of BACE1 expression–
implications for Alzheimer’s disease. Prog Neurobiol 79, 95-
111.
[42] Jeong SJ, Kim K, Suh YH (1997) Age-related changes in the
expression of Alzheimer’s beta APP in the brain of senescence
accelerated mouse (SAM)-P/10. Neuroreport 8, 1733-1737.
R. Dosunmu et al. / Lifespan Profiles of Alzheimer’s Disease-Associated Genes 229
[43] Brock B, Basha MR, DiPalma K, Anderson A, Harry GJ, Rice
DC,Maloney B, Lahiri DK, Zawia NH (2008) Co–localization
and distribution of cerebral APP and SP1 and its relationship
to amyloidogenesis. J Alzheimers Dis 13, 71-80.
[44] Zohar O, Pick CG, Cavallaro S, Chapman J, Katzav A, Mil-
man A, Alkon DL (2005) Age-dependent differential expres-
sion of BACE splice variants in brain regions of tg2576 mice.
Neurobiol Aging 26, 1167-1175.
[45] Chiocco MJ, Kulnane LS, Younkin L, Younkin S, Evin G,
Lamb BT (2004) Altered amyloid-beta metabolism and depo-
sition in genomic-based beta-secretase transgenic mice. J Biol
Chem 279, 52535-52542.
[46] Sirinathsinghji DJ, RigbyM,Heavens RP, Smith D, Fernandez
JM, Schuligoi R, Hill RG (1995) Increased messenger RNA
expression of the 695 and 751 amino acid isoforms of the
beta-amyloid protein precursor in the thalamus of 17-year-old
cynomolgus (Macaca fascicularis) monkeys.Neuroscience 65,
51-57.
[47] Koo EH, Sisodia SS, Cork LC, Unterbeck A, Bayney RM,
Price DL (1990) Differential expression of amyloid precursor
protein mRNAs in cases of Alzheimer’s disease and in aged
nonhuman primates. Neuron 4, 97-104.
[48] Tanaka S, Liu L, Kimura J, Shiojiri S, Takahashi Y, Kitaguchi
N, Nakamura S, Ueda K (1992) Age-related changes in
the proportion of amyloid precursor protein mRNAs in
Alzheimer’s disease and other neurological disorders. Brain
Res Mol Brain Res 15, 303-310.
[49] Robinson CA, Clark AW, Parhad IM, Fung TS, Bou SS (1994)
Gene expression in Alzheimer neocortex as a function of age
and pathologic severity. Neurobiol Aging 15, 681-690.
[50] Flood FM, Cowburn RF, Johnston JA (1997) Presenilin-1,
amyloid precursor protein and amyloid precursor-like protein
2 mRNA levels in human superior frontal cortex during aging.
Neurosci Lett 235, 17-20.
[51] Preece P, Cairns NJ (2003) Quantifying mRNA in postmortem
human brain: influence of gender, age at death, postmortem
interval, brain pH, agonal state and inter-lobe mRNAvariance.
Brain Res Mol Brain Res 118, 60-71.
[52] Bolin CM, Basha R, Cox D, Zawia NH, Maloney B, Lahiri
DK, Cardozo-Pelaez F (2006) Exposure to lead and the devel-
opmental origin of oxidative DNA damage in the aging brain.
FASEB J 20, 788-790.
[53] Basha MR, Murali M, Siddiqi HK, Ghosal K, Siddiqi OK,
Lashuel HA, Ge YW, Lahiri DK, Zawia NH (2005) Lead
(Pb) exposure and its effect on APP proteolysis and Abeta
aggregation. FASEB J 19, 2083-2084.
[54] Song W, Lahiri DK (1998) Molecular cloning of the promoter
of the gene encoding the Rhesus monkey beta-amyloid pre-
cursor protein: structural characterization and a comparative
study with other species. Gene 217, 151-164.
[55] Weise A, Lalonde S, Kuhn C, Frommer WB, Ward JM (2008)
Introns control expression of sucrose transporter LeSUT1 in
trichomes, companion cells and in guard cells. Plant Mol Biol
68, 251-262.
[56] Blount AL, Vaughan JM, Vale WW, Bilezikjian LM (2008)
A Smad-binding element in intron 1 participates in activin-
dependent regulation of the follistatin gene. J Biol Chem 283,
7016-7026.
[57] Ge Y-W, Maloney B, Sambamurti K, Lahiri DK (2004) Func-
tional characterization of the 5’ flanking region of the BACE
gene: identification of a 91 bp fragment involved in basal level
of BACE promoter expression. FASEB J 18, 1037-1039.
[58] Soucek T, Cumming R, Dargusch R, Maher P, Schubert D
(2003) The regulation of glucose metabolism by HIF-1 medi-
ates a neuroprotective response to amyloid beta peptide. Neu-
ron 39, 43-56.
[59] Zhang X, Zhou K, Wang R, Cui J, Lipton SA, Liao FF, Xu
H, Zhang YW (2007) Hypoxia-inducible factor 1alpha (HIF-
1alpha)-mediated hypoxia increases BACE1 expression and
beta-amyloid generation. J Biol Chem 282, 10873-10880.
[60] MacKenzie F, Duriez P, Wong F, Noseda M, Karsan A
(2004) Notch4 inhibits endothelial apoptosis via RBP-Jkappa-
dependent and -independent pathways. J Biol Chem 279,
11657-11663.
[61] Jones FS, Meech R (1999) Knockout of REST/NRSF shows
that the protein is a potent repressor of neuronally expressed
genes in non-neural tissues. Bioessays 21, 372-376.
[62] He ML, Chen Y, Peng Y, Jin D, Du D, Wu J, Lu P, Lin MC,
Kung HF (2002) Induction of apoptosis and inhibition of cell
growth by developmental regulator hTBX5. Biochem Biophys
Res Commun 297, 185-192.
[63] Roussigne M, Cayrol C, Clouaire T, Amalric F, Girard JP
(2003) THAP1 is a nuclear proapoptotic factor that links
prostate-apoptosis-response-4 (Par-4) to PML nuclear bodies.
Oncogene 22, 2432-2442.
[64] Levy S, Avni D, Hariharan N, Perry RP, Meyuhas O (1991)
Oligopyrimidine tract at the 5’ end of mammalian ribosomal
protein mRNAs is required for their translational control. Proc
Natl Acad Sci U S A 88, 3319-3323.
[65] Venti A, Giordano T, Eder P, Bush AI, Lahiri DK, Greig NH,
Rogers JT (2004) The integrated role of desferrioxamine and
phenserine targeted to an iron-responsive element in the APP-
mRNA 5’-untranslated region. Ann N Y Acad Sci 1035, 34-48.
[66] Morse LJ, Payton SM, Cuny GD, Rogers JT (2004) FDA-
preapproved drugs targeted to the translational regulation and
processing of the amyloid precursor protein. J Mol Neurosci
24, 129-136.
[67] Lytle JR, Yario TA, Steitz JA (2007) Target mRNAs are re-
pressed as efficiently by microRNA-binding sites in the 5’
UTR as in the 3’ UTR. Proc Natl Acad Sci U S A 104, 9667-
9672.
[68] Verrotti AC, Thompson SR, Wreden C, Strickland S, Wickens
M (1996) Evolutionary conservation of sequence elements
controlling cytoplasmic polyadenylylation.ProcNatl Acad Sci
U S A 93, 9027-9032.
[69] Young-Pearse TL, Bai J, Chang R, Zheng JB, LoTurco JJ,
Selkoe DJ (2007) A critical function for beta-amyloid precur-
sor protein in neuronal migration revealed by in utero RNA
interference. J Neurosci 27, 14459-14469.
[70] Porayette P, Gallego MJ,Kaltcheva MM,Meethal SV, Atwood
CS (2007) Amyloid-beta precursor protein expression and
modulation in human embryonic stem cells: a novel role for
human chorionic gonadotropin. Biochem Biophys Res Com-
mun 364, 522-527.
[71] Vasudevan S, Tong Y, Steitz JA (2007) Switching from repres-
sion to activation: microRNAs can up-regulate translation.
Science 318, 1931-1934.
[72] Nistor M, Don M, Parekh M, Sarsoza F, Goodus M, Lopez
GE, Kawas C, Leverenz J, Doran E, Lott IT, Hill M, Head
E (2007) Alpha- and beta-secretase activity as a function of
age and beta-amyloid in Down syndrome and normal brain.
Neurobiol Aging 28, 1493-1506.
[73] Shiiki T, Ohtsuki S, Kurihara A, Naganuma H, Nishimura K,
Tachikawa M, Hosoya K, Terasaki T (2004) Brain insulin im-
pairs amyloid-beta(1-40) clearance from the brain. J Neurosci
24, 9632-9637.
[74] Maloney B, Ge Y-W, Alley GM, Lahiri DK (2007) Important
Differences between human and mouse APOEgene promoters
230 R. Dosunmu et al. / Lifespan Profiles of Alzheimer’s Disease-Associated Genes
with implications for Alzheimer’s disease. J Neurochem 103,
1237-1257.
[75] Wu J, Basha MR, Brock B, Maloney B, Cox D, Harry J,
Cardozo-Paleaz F, Rice DC, Lahiri DK, Zawia NH (2008)
Alzheimer’s disease (AD)-like pathology in aged monkeys af-
ter infantile exposure to environmental metal lead (Pb): evi-
dence for a developmental origin and environmental link for
AD. J Neurosci 28, 3-9.
[76] Chan A, Shea TB (2006) Supplementation with apple juice
attenuates presenilin-1 overexpression during dietary and
genetically-induced oxidative stress. J AlzheimersDis 10, 353-
358.
[77] Lahiri DK, Maloney B, Basha MR, Ge YW, Zawia NH (2007)
How and when environmental agents and dietary factors affect
the course of Alzheimer’s disease: the LEARn model (Latent
Early Associated Regulation) may explain the triggering of
AD. Curr Alzheimer Res 4, 219-228.
[78] Cohen J (2007) Relative differences: The myth of 1%. Science
316, 1836.
[79] Lahiri DK, Maloney B (2006) Genes are not our destiny:
the somatic epitype bridges between the genotype and the
phenotype. Nat Rev Neurosci 7, doi:10.1038/nrn2022-c1.
[80] Beck M, Bigl V, Rossner S (2003) Guinea pigs as a nontrans-
genic model for APP processing in vitro and in vivo. Neu-
rochem Res 28, 637-644.
[81] Hattori M, Tsukahara F, Furuhata Y, Tanahashi H, Hirose M,
Saito M, Tsukuni S, Sakaki Y (1997) A novel method for
making nested deletions and its application for sequencing of
a 300 kb region of human APP locus. Nucleic Acids Res 25,
1802-1808.
View publication stats
